Literature DB >> 25458958

Impact of microsatellite instability on survival of endometrial cancer patients.

Daiva Kanopienė1, Giedrė Smailytė2, Jolanta Vidugirienė3, Jeff Bacher3.   

Abstract

BACKGROUND AND
OBJECTIVE: Endometrial cancer (EC) is the most commonly diagnosed gynecologic malignancy among women worldwide and may be classified on the basis of different molecular, pathologic and genetic alterations, including microsatellite instability (MSI). Although MSI is associated with a more favorable outcome in colorectal cancer, its relationship with prognosis in EC cancer is not yet clear. The aim of our study is to identify whether MSI correlates with survival of patients in EC.
MATERIALS AND METHODS: We examined MSI status and survival of 109 women. MSI was detected by employing the Promega MSI Analysis System, which used 5 mononucleotides markers (BAT-25, BAT-26, NR-21, NR-24, and MONO-27) to identify MSI in a tumor and normal tissue DNA and 2 pentanucleotide markers (Penta C and Penta D) for specimen identification. Median follow-up of patients was 40.4 months (range 5.2-47.9). Survival was estimated by the Kaplan-Meier method and Cox regression analysis was used to assess the effects of different variables on patient survival.
RESULTS: MSI-high was detected in 15.6% EC cases, all of which were associated with endometrioid type histology. Kaplan-Meier survival analysis showed no statistically significant differences between patients with MSI-high and MSI stable tumors (P=0.4) and multivariate analysis concluded that MSI status remained insignificant after stage, histology and tumor grade adjustment (P=0.5).
CONCLUSIONS: Our study showed no statistically significant relationship between MSI-high and survival of endometrial cancer patients.
Copyright © 2014 Lithuanian University of Health Sciences. Production and hosting by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Endometrial cancer; Microsatellite instability; Survival

Mesh:

Year:  2014        PMID: 25458958     DOI: 10.1016/j.medici.2014.09.002

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  8 in total

1.  Deterministic Role of CEA and MSI Status in Predicting Outcome of CRC Patients: a Perspective Study Amongst Hospital Attending Eastern Indian Populations.

Authors:  Banerjee Koyel; Das Priyabrata; Bhattacharya Rittwika; Dasgupta Swati; Mukhopadhyay Soma; Basak Jayasri; Mukhopadhyay Ashis
Journal:  Indian J Surg Oncol       Date:  2017-04-08

2.  Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  D Scott McMeekin; David L Tritchler; David E Cohn; David G Mutch; Heather A Lankes; Melissa A Geller; Matthew A Powell; Floor J Backes; Lisa M Landrum; Richard Zaino; Russell D Broaddus; Nilsa Ramirez; Feng Gao; Shamshad Ali; Kathleen M Darcy; Michael L Pearl; Paul A DiSilvestro; Shashikant B Lele; Paul J Goodfellow
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

3.  Differences in Microsatellite Instability Profiles between Endometrioid and Colorectal Cancers: A Potential Cause for False-Negative Results?

Authors:  Yang Wang; Chanjuan Shi; Rosana Eisenberg; Cindy L Vnencak-Jones
Journal:  J Mol Diagn       Date:  2016-11-01       Impact factor: 5.568

Review 4.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16

5.  Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.

Authors:  Michele Moschetta; Gabriel Mak; Joana Hauser; Catriona Davies; Mario Uccello; Hendrik-Tobias Arkenau
Journal:  Exp Hematol Oncol       Date:  2017-01-10

6.  Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer.

Authors:  Hitomi Yamashita; Kentaro Nakayama; Masako Ishikawa; Kohei Nakamura; Tomoka Ishibashi; Kaori Sanuki; Ruriko Ono; Hiroki Sasamori; Toshiko Minamoto; Kouji Iida; Razia Sultana; Noriyoshi Ishikawa; Satoru Kyo
Journal:  Oncotarget       Date:  2017-12-31

7.  Endometrial cancer risk and survival by tumor MMR status.

Authors:  Penelope M Webb; Amanda B Spurdle; Christina M Nagle; Tracy A O'Mara; Yen Tan; Daniel D Buchanan; Andreas Obermair; Penny Blomfield; Michael A Quinn
Journal:  J Gynecol Oncol       Date:  2018-02-23       Impact factor: 4.401

8.  Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters.

Authors:  Atif Ali Hashmi; Ghazala Mudassir; Rozina Nooreen Hashmi; Muhammad Irfan; Huda Asif; Erum Yousuf Khan; Syed Muhammad Abu Bakar; Naveen Faridi
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.